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Abstract
Background: GM2 gangliosidosis-AB variants a rare autosomal recessive neurodegenerative disorder occurring due
to deficiency of GM2 activator protein resulting from the mutation in GM2A gene. Only seven mutations in nine
cases have been reported from different population except India.
Case presentation: Present case is a one year old male born to 3rd degree consanguineous Indian parents from
Maharashtra. He was presented with global developmental delay, hypotonia and sensitive to hyperacusis. Horizontal
nystagmus and cherry red spot was detected during ophthalmic examination. MRI of brain revealed putaminal
hyperintensity and thalamic hypointensity with some unmyelinated white matter in T2/T1 weighted images. Initially
he was suspected having Tay-Sachs disease and finally diagnosed as GM2 gangliosidosis, AB variant due to
truncated protein caused by nonsense mutation c.472 G > T (p.E158X) in GM2Agene.
Conclusion: Children with phenotypic presentation as GM2 gangliosidosis (Tay-Sachs or Sandhoff disease) and normal
enzyme activity of β-hexosaminidase-A and -B in leucocytes need to be investigated for GM2 activator protein deficiency.
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Background
GM2 gangliosides are the glycosphingolipids present in
the outer layer of mammalian cells that are enriched on
the neuronic surfaces [1]. In normal condition, glyco-
sphingolipids are catabolized by lysosomal exohydrolases
and are unique as they require synthesis and interaction
of three-gene products;α and β subunits of lysosomal
glycosidase enzyme-β-hexosaminidase (EC 3.2.1.52) and
presence of a small non-enzymatic lipid binding protein
as an activator [1]. This tiny glycolipid transporter GM2
activator protein (GM2AP), acts as a substrate specific
cofactor for the degradation of GM2 ganglioside by the
enzyme β-hexosaminidase. Hence, deficiency of any of
these protein that are encoded by the HEXA, HEXB and
GM2A gene causes excessive intra lysosomal accumula-
tion of GM2 and related glycolipids especially in
neuronal cells resulting in GM2 gangliodosis [2].
Mutations in the HEXA gene encoding the α-chain of
(β-hexosaminidase-A) Hex-A leads to Tay-Sachs disease
or B variant, while mutations in the β-chain encompass-
ing HEXB gene leads to deficiency of both Hex-A and
Hex-B (total-Hex) causing Sandhoff disease or O variant.
These disorders are fairly common in the Indian popula-
tion [3]-[4]. The third variant of GM2 gangliosidosis,
known as AB variant (OMIM-272750), is rarely encoun-
tered and only nine cases are reported till date world
wide as described in Table 1 [2], [5]-[6]. This form of
GM2 gangliosidosis is indistinguishable from infantile
form of Tay-Sachs disease due to its phenotypic similar-
ity. Here we report a novel case with a review of GM2A
activator protein deficiency.
Clinical presentation
Proband was a third child born to young third degree con-
sanguineous parents from Maharashtra. One elder sister
died at the age of 1½ years having similar complaints.
The case under report had a normal antenatal and
perinatal history and was born with a birth weight of
3.05 kg at term. At the age of 12 months, global
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development delay with absence of social smile and
poor head control was noticed. He was detected
having hypotonia with a significantly poor tone in the
limbs compared to the axial movements. The visual
responses seemed quite poor. Head circumference
was normal and no dysmorphism was observed. The
child did not show any Mongolian patches on lumbo-
sacral area which was detected, in our earlier case
series with Tay-Sachs disease [7].
On clinical examination, there was no organomegaly.
Significant hyperacusis was noted even to the most triv-
ial sounds. Fundus examination showed bilateral cherry
red spot in macula and horizontal nystagmus. Magnetic
Resonance Imaging (MRI) scan of brain revealed puta-
minal hyperintensity and thalamic hypointensity with
some unmyelinated white matter in T2/T1 weighted im-
ages (Fig 1(a)-(b)), which is commonly detected in cases
with GM2 gangliosidosis.
Table 1 Review of molecularly proven cases of GM2 Gangliosidosis-AB variant
Case Mutation Exon Predicted protien change Author Ethnicity Year
1 c.412T>C (p.C107R)a
(Homozygous)
3 Reduced interaction with Hex A Schroder et al. [15] US Black 1991
2 c.412T>C (p.C138R)a
(Homozygous)
3 Reduced interaction with Hex A Xie et al. [16] US Black 1992
3 c.506G>C (p.R169P)
(Homozygous)
4 Pre-matured protein degradation Schroder et al. [17] Indian 1993
4 c.262_264delAAG(p.88Kdel)
(Homozygous)
3 Absence of mature CRM Schepers et al. [14] Saudi Arabia 1996
5 c.410delA (p.H137PfsX34)
(Homozygous)
3 Absence of mature CRM Schepers et al. [14] Spanish 1996
6 c.160G>T (p.E54X)
(Homozygous)





4 Pre-matured protein degradation Kolodny et al. [18] Indian 2008
8 c. 160G>T (p.E54X)
(Homozygous)
2 Absence of mRNA or CRM Renaud et al. [19] Hmong 2015
9 c.164C>T (p.P55L)
(Homozygous)
2 Reduced interaction with Hex A Salih et al. [6] Saudi Arabia 2015
10 c.472G>T (p.E158X)
(Homozygous)
4 Absence of mRNA or CRM Present case Indian 2015
a The mutations identified by Schroder et al. (1991) (CYS107ARG) and Xie et al. (1992) (CYS138ARG) are the same but derived from different amino acid
numbering systems
Fig. 1 (a)-(b): Initial T2 weighted MRI pictures of brain revealed (a) putaminal hyperintensity and (b) thalamic hypointensity with some
unmyelinated white matter in T2/T1 weighted images
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After obtaining institutional ethics committee approval
and informed written consent, further study was carried
out. The blood samples of the proband and their parents
were taken for the study. Clinical presentation was
pointing towards GM2 gangliosidosis. Enzyme activity
was determined by fluorimetric method using specific
synthetic substrate. Hex-A was assayed with a sulphated
substrate 4-methylumbelliferyl-N-acetyl-β-D-glucosamine-
6-sulphate (MUGS) whereas total hexosaminidase (total-
Hex) was measured from the hydrolysis of the synthetic
substrate 4-methylumbelliferyl-Nacetyl-β-D-glucosamine
(MUG) that releases fluorescent 4-methylumbelliferone
when acted upon by β-hexosaminidase [8]. Enzyme activ-
ities for Hex-A [102 nmol/hr/mg protein; NR: 69.0 -
659.0 nmol/hr/mg protein] and total-Hex [414.9 nmol/hr/
mg protein; NR: 288.4 – 1758.0 nmol/hr/mg protein] were
found to be normal. This makes it highly unlikely for Tay-
Sachs or B variant and Sandhoff disease or O variant. In
presence of strong clinical presentation and normal lyso-
somal enzyme activity; GM2 gangliosidosis activator defi-
ciency leading to AB variant was carried out by mutation
analysis encompassing GM2 activator (GM2A) gene.
Molecular analysis was carried out by bi-directional se-
quencing of the coding region of GM2A gene together
with intronic flanking region using the primer pairs as
described earlier [9]. The amplification was carried out
in a thermal cycler (ABI 2720) with 5-min denaturation
at 94 °C followed by forty-three cycles each consisting of
30 s denaturation at 94 °C, 30 s of annealing at 54 °C,
and 30 seconds extension at 72 °C. Final extension was
carried out at 72°C for 10 min.
The GM2A gene analysis revealed a novel homozygous
c.472G > T (p.E158X) nonsense mutation in exon-
4confirming the diagnosis of GM2AP deficiency leading
toGM2 gangliosidosis, AB variant (Fig. 2). Parents were
found to be heterozygous for the same mutation. The
deleterious effect of the mutation was further confirmed
using bioinformatics tool; Mutation taster program.
Discussion
GM2 activator deficiency as a cause of GM2 gangliosidosis
is a rarely diagnosed sphingolipid disorder. Conzelmann
and Sandhoff (1978) were the first one to present an evi-
dence of defective activating factor necessary for degrad-
ation of GM2 ganglioside [10]. This was followed by
demonstration of GM2 activator protein deficiency in liver
cells in Non-Jewish child from England by Hechtmen et
al. in 1982 [11]. Subsequently nine molecularly proven
cases of GM2 activator deficiency from different parts of
the world as summarized in Table 1 have been reported.
Here we present tenth case having a novel mutation in
GM2A gene. Clinically, proband was indistinguishable
from classical infantile Tay-Sachs disease. However, due to
the normal activity of Hex-A and total-hex enzymes in
leucocytes, the c.DNA analysis of GM2A gene was carried
out. The case under study showed homoallelic nonsense
mutation (p.E158X) in GM2A gene, due to replacement of
nucleotide Guanine (G) by Thymine (T) at c.DNA pos-
ition 472 (c.472G > T). This is a novel pathogenic variant
found to be responsible for a GM2AP deficiency in our
patient with AB variant of GM2 gangliosidosis.
To the best of our knowledge, this mutation (p.E158X)
is neither reported in any ethnic group, nor present in
the dbSNP database (http://www.ncbi.nlm.nih.gov/SNP/).
This variation has not been reported in the 1000 genome
database and this region is conserved across species. In-
silico analysis using the Mutation taster program suggests
a probably damaging nature of the mutation. A subunit
lacking the last 36 C-terminal residues is likely to make
the protein non-functional. This premature stop codon is
likely to have produced a truncated protein as the stop
codon occurred near 3’end of the gene, which leads to
Fig. 2 Bi-directional sequence chromatogram detected homozygous nonsense mutation viz. c.472 G > T (p.E158X) in exon-4 of GM2A gene
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unstable mRNAs. It is also likely that the proteins synthe-
sized in the endothelium reticulum (ER) undergo a quality
control check by the resident ER system that recognizes
abnormal proteins and degrades them [12]. Though func-
tional study has not been carried out in our case it is likely
that nonsense point mutation in the present case seems to
have produced a premature stop codon thus affecting the
stability of the mutated protein or its Hex-A binding
capabilities [13] or perhaps leading to early degradation in
the ER or Golgi bodies [14], thus portraying the clinical
presentation.
Only seven mutations in nine patients have been
documented in the GM2A gene till date and all patients
were found to be homozygous for individual mutant
alleles associated with complete absence of GM2 gan-
glioside cleavage [2], [5, 6, 9, 14–19]. Earlier published
reports have shown steady state levels of activator
mRNA but none were found to have detectable activator
cross reacting material (CRM) in patient’s cells except in
a study reported by Chen et al. (1999) [9] where they
have shown absence of detectable steady state mRNA
nor any CRM.
The homoallelic nonsense mutation detected in the
child was confirmed by the heterozygous state of both
parents. This could be one of the reasons for the early
death of the elder sister. Based on this, family was pro-
vided genetic counseling about the future recurrence
risks of the disease and prevention by prenatal diagnosis.
Conclusion
It can be concluded from this case that children with
global developmental delay and unmyelinated white
matter with normal hexosaminidase study need to be
further investigated for GM2 activator protein
deficiency.
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